138 related articles for article (PubMed ID: 38115178)
1. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract][Full Text] [Related]
2. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
3. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
4. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
[TBL] [Abstract][Full Text] [Related]
5. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
[TBL] [Abstract][Full Text] [Related]
6. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
7. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
[TBL] [Abstract][Full Text] [Related]
8. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
9. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
10. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
[TBL] [Abstract][Full Text] [Related]
12. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
[TBL] [Abstract][Full Text] [Related]
14. Characterization of zolbetuximab in pancreatic cancer models.
Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
[TBL] [Abstract][Full Text] [Related]
15. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
[TBL] [Abstract][Full Text] [Related]
16. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
Konno H; Lin T; Wu R; Dai X; Li S; Wang G; Chen M; Li W; Wang L; Sun BC; Luo Z; Huang T; Chen Y; Zhang J; Ye Q; Bellovin D; Wan B; Kang L; Szeto C; Hsu K; Kabbarah O
Cancer Res Commun; 2022 Sep; 2(9):937-950. PubMed ID: 36922936
[TBL] [Abstract][Full Text] [Related]
17. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
18. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
[TBL] [Abstract][Full Text] [Related]
19. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
Rogers JE; Ajani JA
Curr Opin Oncol; 2024 Apr; ():. PubMed ID: 38726797
[TBL] [Abstract][Full Text] [Related]
20. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Ajani J
Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
